ArticleThe journal of nutrition, health & aging2026
Phenotypic age acceleration and omega-6/omega-3 PUFA ratio in dynamic atrial fibrillation-heart failure transitions: a multistate analysis.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiological aging and dietary fatty acid balance may influence the bidirectional progression between atrial fibrillation (AF) and heart failure (HF); however, most studies focus on single endpoints, overlooking intermediate states.
objectiveTo evaluate the independent and joint associations of phenotypic age acceleration (PhenoAgeAccel) and the plasma omega-6/omega-3 (ω-6/ω-3) polyunsaturated fatty acid (PFUA) ratio with AF-HF transitions, and to examine mediation by lipids and C-reactive protein.
methodsIn a retrospective cohort of 191,091 UK Biobank participants free of baseline cardiovascular disease, PhenoAgeAccel was calculated as the residual from regressing phenotypic age on chronological age. The ω-6/ω-3 ratio was quantified by nuclear magnetic resonance. Incident AF and HF were modeled using clock-forward multistate Markov models for four transitions: baseline to AF, baseline to HF, AF to HF, and HF to AF. These transitions represent sequential disease progression, where either AF or HF may occur first and later progress to AF-HF comorbidity. Hazard ratios (HRs) were estimated per 1-SD increment. Joint exposure and mediation analyses were performed.
resultsOver a median 15.4 years, 10,084 developed AF and 3,117 H F; 1,335 transitioned from AF to HF and 426 from HF to AF. Per 1-SD higher PhenoAgeAccel, risks increased for baseline-to-AF (HR 1.12 [95% CI 1.10-1.15]), baseline-to-HF (1.24 [1.21-1.26]), AF-to-HF (1.12 [1.09-1.15]), and HF-to-AF (1.06 [1.01-1.12]). Per 1-SD higher ω-6/ω-3 ratio, risks rose for baseline-to-AF (1.04 [1.02-1.06]), baseline-to-HF (1.07 [1.05-1.10]), AF-to-HF (1.12 [1.07-1.18]), and HF-to-AF (1.10 [1.01-1.20]). Mediation occurred via triglycerides (up to 38.5% of ω-6/ω-3-AF association) and CRP (up to 10.7% of PhenoAgeAccel-HF association).
conclusionHigher PhenoAgeAccel and ω-6/ω-3 PFUA ratios were independently associated with higher risks of AF-HF transitions, with these associations partly explained by lipid and inflammatory pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.